McIntyre, K., O’Shaughnessy, J., Schwartzberg, L., Glück, S., Berrak, E., Song, J. X., . . . Vahdat, L. T. (2014). Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat.

McIntyre, Kristi, Joyce O’Shaughnessy, Lee Schwartzberg, Stefan Glück, Erhan Berrak, James X. Song, David Cox, و Linda T. Vahdat. "Erratum To: Phase 2 Study of Eribulin Mesylate As First-line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor 2-negative Breast Cancer." Breast Cancer Res Treat 2014.

McIntyre, Kristi, et al. "Erratum To: Phase 2 Study of Eribulin Mesylate As First-line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor 2-negative Breast Cancer." Breast Cancer Res Treat 2014.